Risk of Malignant Progression in Barrett's Esophagus Patients: Results from a Large Population-Based Study
Background Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. We examined the risk of malignant progression in patients with BE using data from the North...
Saved in:
| Published in | JNCI : Journal of the National Cancer Institute Vol. 103; no. 13; pp. 1049 - 1057 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cary, NC
Oxford University Press
06.07.2011
Oxford Publishing Limited (England) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background
Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. We examined the risk of malignant progression in patients with BE using data from the Northern Ireland Barrett's esophagus Register (NIBR), one of the largest population-based registries of BE worldwide, which includes every adult diagnosed with BE in Northern Ireland between 1993 and 2005.
Subjects and Methods
We followed 8522 patients with BE, defined as columnar lined epithelium of the esophagus with or without specialized intestinal metaplasia (SIM), until the end of 2008. Patients with incident adenocarcinomas of the esophagus or gastric cardia or with high-grade dysplasia of the esophagus were identified by matching the NIBR with the Northern Ireland Cancer Registry, and deaths were identified by matching with records from the Registrar General's Office. Incidence of cancer outcomes or high-grade dysplasia was calculated as events per 100 person-years (% per year) of follow-up, and Cox proportional hazard models were used to determine incidence by age, sex, length of BE segment, presence of SIM, macroscopic BE, or low-grade dysplasia. All P values were from two-sided tests.
Results
After a mean of 7.0 years of follow-up, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia, and 36 with high-grade dysplasia. In the entire cohort, incidence of esophageal or gastric cardia cancer or high-grade dysplasia combined was 0.22% per year (95% confidence interval [CI] = 0.19% to 0.26%). SIM was found in 46.0% of patients. In patients with SIM, the combined incidence was 0.38% per year (95% CI = 0.31 to 0.46%). The risk of cancer was statistically significantly elevated in patients with vs without SIM at index biopsy (0.38% per year vs 0.07% per year; hazard ratio [HR] = 3.54, 95% CI = 2.09 to 6.00, P < .001), in men compared with women (0.28% per year vs 0.13% per year; HR = 2.11, 95% CI = 1.41 to 3.16, P < .001), and in patients with low-grade dysplasia compared with no dysplasia (1.40% per year vs 0.17% per year; HR = 5.67, 95% CI = 3.77 to 8.53, P < .001).
Conclusion
We found the risk of malignant progression among patients with BE to be lower than previously reported, suggesting that currently recommended surveillance strategies may not be cost-effective. |
|---|---|
| AbstractList | Background
Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. We examined the risk of malignant progression in patients with BE using data from the Northern Ireland Barrett's esophagus Register (NIBR), one of the largest population-based registries of BE worldwide, which includes every adult diagnosed with BE in Northern Ireland between 1993 and 2005.
Subjects and Methods
We followed 8522 patients with BE, defined as columnar lined epithelium of the esophagus with or without specialized intestinal metaplasia (SIM), until the end of 2008. Patients with incident adenocarcinomas of the esophagus or gastric cardia or with high-grade dysplasia of the esophagus were identified by matching the NIBR with the Northern Ireland Cancer Registry, and deaths were identified by matching with records from the Registrar General's Office. Incidence of cancer outcomes or high-grade dysplasia was calculated as events per 100 person-years (% per year) of follow-up, and Cox proportional hazard models were used to determine incidence by age, sex, length of BE segment, presence of SIM, macroscopic BE, or low-grade dysplasia. All P values were from two-sided tests.
Results
After a mean of 7.0 years of follow-up, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia, and 36 with high-grade dysplasia. In the entire cohort, incidence of esophageal or gastric cardia cancer or high-grade dysplasia combined was 0.22% per year (95% confidence interval [CI] = 0.19% to 0.26%). SIM was found in 46.0% of patients. In patients with SIM, the combined incidence was 0.38% per year (95% CI = 0.31 to 0.46%). The risk of cancer was statistically significantly elevated in patients with vs without SIM at index biopsy (0.38% per year vs 0.07% per year; hazard ratio [HR] = 3.54, 95% CI = 2.09 to 6.00, P < .001), in men compared with women (0.28% per year vs 0.13% per year; HR = 2.11, 95% CI = 1.41 to 3.16, P < .001), and in patients with low-grade dysplasia compared with no dysplasia (1.40% per year vs 0.17% per year; HR = 5.67, 95% CI = 3.77 to 8.53, P < .001).
Conclusion
We found the risk of malignant progression among patients with BE to be lower than previously reported, suggesting that currently recommended surveillance strategies may not be cost-effective. Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. We examined the risk of malignant progression in patients with BE using data from the Northern Ireland Barrett's esophagus Register (NIBR), one of the largest population-based registries of BE worldwide, which includes every adult diagnosed with BE in Northern Ireland between 1993 and 2005. We followed 8522 patients with BE, defined as columnar lined epithelium of the esophagus with or without specialized intestinal metaplasia (SIM), until the end of 2008. Patients with incident adenocarcinomas of the esophagus or gastric cardia or with high-grade dysplasia of the esophagus were identified by matching the NIBR with the Northern Ireland Cancer Registry, and deaths were identified by matching with records from the Registrar General's Office. Incidence of cancer outcomes or high-grade dysplasia was calculated as events per 100 person-years (% per year) of follow-up, and Cox proportional hazard models were used to determine incidence by age, sex, length of BE segment, presence of SIM, macroscopic BE, or low-grade dysplasia. All P values were from two-sided tests. After a mean of 7.0 years of follow-up, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia, and 36 with high-grade dysplasia. In the entire cohort, incidence of esophageal or gastric cardia cancer or high-grade dysplasia combined was 0.22% per year (95% confidence interval [CI] = 0.19% to 0.26%). SIM was found in 46.0% of patients. In patients with SIM, the combined incidence was 0.38% per year (95% CI = 0.31 to 0.46%). The risk of cancer was statistically significantly elevated in patients with vs without SIM at index biopsy (0.38% per year vs 0.07% per year; hazard ratio [HR] = 3.54, 95% CI = 2.09 to 6.00, P < .001), in men compared with women (0.28% per year vs 0.13% per year; HR = 2.11, 95% CI = 1.41 to 3.16, P < .001), and in patients with low-grade dysplasia compared with no dysplasia (1.40% per year vs 0.17% per year; HR = 5.67, 95% CI = 3.77 to 8.53, P < .001). We found the risk of malignant progression among patients with BE to be lower than previously reported, suggesting that currently recommended surveillance strategies may not be cost-effective. Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. We examined the risk of malignant progression in patients with BE using data from the Northern Ireland Barrett's esophagus Register (NIBR), one of the largest population-based registries of BE worldwide, which includes every adult diagnosed with BE in Northern Ireland between 1993 and 2005.BACKGROUNDBarrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. We examined the risk of malignant progression in patients with BE using data from the Northern Ireland Barrett's esophagus Register (NIBR), one of the largest population-based registries of BE worldwide, which includes every adult diagnosed with BE in Northern Ireland between 1993 and 2005.We followed 8522 patients with BE, defined as columnar lined epithelium of the esophagus with or without specialized intestinal metaplasia (SIM), until the end of 2008. Patients with incident adenocarcinomas of the esophagus or gastric cardia or with high-grade dysplasia of the esophagus were identified by matching the NIBR with the Northern Ireland Cancer Registry, and deaths were identified by matching with records from the Registrar General's Office. Incidence of cancer outcomes or high-grade dysplasia was calculated as events per 100 person-years (% per year) of follow-up, and Cox proportional hazard models were used to determine incidence by age, sex, length of BE segment, presence of SIM, macroscopic BE, or low-grade dysplasia. All P values were from two-sided tests.SUBJECTS AND METHODSWe followed 8522 patients with BE, defined as columnar lined epithelium of the esophagus with or without specialized intestinal metaplasia (SIM), until the end of 2008. Patients with incident adenocarcinomas of the esophagus or gastric cardia or with high-grade dysplasia of the esophagus were identified by matching the NIBR with the Northern Ireland Cancer Registry, and deaths were identified by matching with records from the Registrar General's Office. Incidence of cancer outcomes or high-grade dysplasia was calculated as events per 100 person-years (% per year) of follow-up, and Cox proportional hazard models were used to determine incidence by age, sex, length of BE segment, presence of SIM, macroscopic BE, or low-grade dysplasia. All P values were from two-sided tests.After a mean of 7.0 years of follow-up, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia, and 36 with high-grade dysplasia. In the entire cohort, incidence of esophageal or gastric cardia cancer or high-grade dysplasia combined was 0.22% per year (95% confidence interval [CI] = 0.19% to 0.26%). SIM was found in 46.0% of patients. In patients with SIM, the combined incidence was 0.38% per year (95% CI = 0.31 to 0.46%). The risk of cancer was statistically significantly elevated in patients with vs without SIM at index biopsy (0.38% per year vs 0.07% per year; hazard ratio [HR] = 3.54, 95% CI = 2.09 to 6.00, P < .001), in men compared with women (0.28% per year vs 0.13% per year; HR = 2.11, 95% CI = 1.41 to 3.16, P < .001), and in patients with low-grade dysplasia compared with no dysplasia (1.40% per year vs 0.17% per year; HR = 5.67, 95% CI = 3.77 to 8.53, P < .001).RESULTSAfter a mean of 7.0 years of follow-up, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia, and 36 with high-grade dysplasia. In the entire cohort, incidence of esophageal or gastric cardia cancer or high-grade dysplasia combined was 0.22% per year (95% confidence interval [CI] = 0.19% to 0.26%). SIM was found in 46.0% of patients. In patients with SIM, the combined incidence was 0.38% per year (95% CI = 0.31 to 0.46%). The risk of cancer was statistically significantly elevated in patients with vs without SIM at index biopsy (0.38% per year vs 0.07% per year; hazard ratio [HR] = 3.54, 95% CI = 2.09 to 6.00, P < .001), in men compared with women (0.28% per year vs 0.13% per year; HR = 2.11, 95% CI = 1.41 to 3.16, P < .001), and in patients with low-grade dysplasia compared with no dysplasia (1.40% per year vs 0.17% per year; HR = 5.67, 95% CI = 3.77 to 8.53, P < .001).We found the risk of malignant progression among patients with BE to be lower than previously reported, suggesting that currently recommended surveillance strategies may not be cost-effective.CONCLUSIONWe found the risk of malignant progression among patients with BE to be lower than previously reported, suggesting that currently recommended surveillance strategies may not be cost-effective. Background Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. We examined the risk of malignant progression in patients with BE using data from the Northern Ireland Barrett's esophagus Register (NIBR), one of the largest population-based registries of BE worldwide, which includes every adult diagnosed with BE in Northern Ireland between 1993 and 2005. Subjects and Methods We followed 8522 patients with BE, defined as columnar lined epithelium of the esophagus with or without specialized intestinal metaplasia (SIM), until the end of 2008. Patients with incident adenocarcinomas of the esophagus or gastric cardia or with high-grade dysplasia of the esophagus were identified by matching the NIBR with the Northern Ireland Cancer Registry, and deaths were identified by matching with records from the Registrar General's Office. Incidence of cancer outcomes or high-grade dysplasia was calculated as events per 100 person-years (% per year) of follow-up, and Cox proportional hazard models were used to determine incidence by age, sex, length of BE segment, presence of SIM, macroscopic BE, or low-grade dysplasia. All P values were from two-sided tests. Results After a mean of 7.0 years of follow-up, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia, and 36 with high-grade dysplasia. In the entire cohort, incidence of esophageal or gastric cardia cancer or high-grade dysplasia combined was 0.22% per year (95% confidence interval [CI] = 0.19% to 0.26%). SIM was found in 46.0% of patients. In patients with SIM, the combined incidence was 0.38% per year (95% CI = 0.31 to 0.46%). The risk of cancer was statistically significantly elevated in patients with vs without SIM at index biopsy (0.38% per year vs 0.07% per year; hazard ratio [HR] = 3.54, 95% CI = 2.09 to 6.00, P < .001), in men compared with women (0.28% per year vs 0.13% per year; HR = 2.11, 95% CI = 1.41 to 3.16, P < .001), and in patients with low-grade dysplasia compared with no dysplasia (1.40% per year vs 0.17% per year; HR = 5.67, 95% CI = 3.77 to 8.53, P < .001). Conclusion We found the risk of malignant progression among patients with BE to be lower than previously reported, suggesting that currently recommended surveillance strategies may not be cost-effective. Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. Bhat et al examined the risk of malignant progression in patients with BE using data from the Northern Ireland Barrett's esophagus Register, one of the largest population-based registries of BE worldwide, which includes every adult diagnosed with BE in Northern Ireland between 1993 and 2005. After a mean of 7.0 years of follow-up, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia, and 36 with high-grade dysplasia. In the entire cohort, incidence of esophageal or gastric cardia cancer or high-grade dysplasia combined was 0.22% per year (95% confidence interval [CI] = 0.19% to 0.26%). They found the risk of malignant progression among patients with BE to be lower than previously reported, suggesting that currently recommended surveillance strategies may not be cost-effective. |
| Author | Coleman, Helen G. Gavin, Anna T. Murray, Liam J. McManus, Damian T. Bhat, Shivaram Johnston, Brian T. Yousef, Fouad |
| AuthorAffiliation | Affiliations of authors: Centre for Public Health, Queens University Belfast, Institute of Clinical Sciences Building, Belfast, Northern Ireland (SB, HGC, FY, LJM); Department of Gastroenterology, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland (BTJ); Department of Pathology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland (DM); Northern Ireland Cancer Registry, Centre for Public Health, Queens University Belfast, Belfast, Northern Ireland (ATG) |
| AuthorAffiliation_xml | – name: Affiliations of authors: Centre for Public Health, Queens University Belfast, Institute of Clinical Sciences Building, Belfast, Northern Ireland (SB, HGC, FY, LJM); Department of Gastroenterology, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland (BTJ); Department of Pathology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland (DM); Northern Ireland Cancer Registry, Centre for Public Health, Queens University Belfast, Belfast, Northern Ireland (ATG) |
| Author_xml | – sequence: 1 givenname: Shivaram surname: Bhat fullname: Bhat, Shivaram email: shiv_bhat@doctors.org.uk – sequence: 2 givenname: Helen G. surname: Coleman fullname: Coleman, Helen G. – sequence: 3 givenname: Fouad surname: Yousef fullname: Yousef, Fouad – sequence: 4 givenname: Brian T. surname: Johnston fullname: Johnston, Brian T. – sequence: 5 givenname: Damian T. surname: McManus fullname: McManus, Damian T. – sequence: 6 givenname: Anna T. surname: Gavin fullname: Gavin, Anna T. – sequence: 7 givenname: Liam J. surname: Murray fullname: Murray, Liam J. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24343137$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21680910$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0ktv1DAQAGALFdFt4cQdWUi0BxTq18YJB6S2Kg9pEasCZ2viOKlD1g62g9R_j8tueVQIfLEsfx7NeOYA7TnvDEKPKXlBSc1PBqftSTsERvg9tKCiJAWjZLmHFoQwWVSVFPvoIMaB5FUz8QDtM1pWpKZkgYZLG79g3-H3MNregUt4HXwfTIzWO2wdPoMQTErHEV9EP11BP0e8hmSNS_ElvjRxHlPEXfAbDHgFoTd47ad5zMS74gyiafHHNLfXD9H9DsZoHu32Q_T59cWn87fF6sObd-enq0IvyzIVpuuapm0oaKIbQQVURLesyyfRMkZlqQkIXWlTGk5yHaw0TcsItLXRHW81P0SvtnGnudmYVudEA4xqCnYD4Vp5sOrPG2evVO-_KV5yRijNAY53AYL_OpuY1MZGbcYRnPFzVFVdU1ELtvy_lEvJuKyqLJ_ekYOfg8v_kFEtCZeyzOjJ75n_TPm2XRk82wGIGsYuQO59_OUEF5xymR3dOh18jMF0Stv0oyG5YDsqStTN6Kib0VHb0clvnt95cxv27_poq_08_RN-ByO11ZA |
| CODEN | JNCIEQ |
| CitedBy_id | crossref_primary_10_1093_dote_doz024 crossref_primary_10_3322_caac_21185 crossref_primary_10_1016_j_gastrohep_2022_09_005 crossref_primary_10_1007_s00535_013_0862_6 crossref_primary_10_1016_j_jfma_2025_03_006 crossref_primary_10_1042_CS20180828 crossref_primary_10_3389_fcell_2023_1151790 crossref_primary_10_1053_j_gastro_2016_02_036 crossref_primary_10_1016_j_canep_2015_10_013 crossref_primary_10_1097_PAS_0000000000000598 crossref_primary_10_1136_gutjnl_2013_305506 crossref_primary_10_1007_s00464_020_07950_5 crossref_primary_10_5056_jnm_2013_19_2_261 crossref_primary_10_5694_mja16_00796 crossref_primary_10_1136_flgastro_2016_100712 crossref_primary_10_1016_j_pdpdt_2019_01_012 crossref_primary_10_1016_j_bpg_2015_09_010 crossref_primary_10_1097_MPA_0000000000000750 crossref_primary_10_1136_gutjnl_2023_331557 crossref_primary_10_14309_ctg_0000000000000014 crossref_primary_10_1016_j_cgh_2017_11_044 crossref_primary_10_1053_j_gastro_2015_08_048 crossref_primary_10_1016_j_dld_2013_09_025 crossref_primary_10_1097_MCG_0000000000000742 crossref_primary_10_1159_000488489 crossref_primary_10_1016_j_bpg_2015_01_001 crossref_primary_10_1016_j_jnma_2018_09_008 crossref_primary_10_1038_bjc_2016_219 crossref_primary_10_3390_cancers13030582 crossref_primary_10_1371_journal_pone_0133403 crossref_primary_10_1177_2050640617707862 crossref_primary_10_1016_j_med_2016_01_002 crossref_primary_10_1038_nrgastro_2013_150 crossref_primary_10_1055_a_1765_7197 crossref_primary_10_1158_1055_9965_EPI_14_0384 crossref_primary_10_3748_wjg_v22_i17_4297 crossref_primary_10_1158_1940_6207_CAPR_16_0170 crossref_primary_10_1007_s00464_014_3548_0 crossref_primary_10_1136_bmjgast_2022_001091 crossref_primary_10_1016_j_jtcvs_2012_01_023 crossref_primary_10_1016_j_gtc_2021_08_009 crossref_primary_10_1093_dote_doaa009 crossref_primary_10_1136_bmjgast_2020_000494 crossref_primary_10_1177_1756283X12446668 crossref_primary_10_1016_j_soc_2016_10_004 crossref_primary_10_1002_jbio_201960132 crossref_primary_10_1177_17588359241303066 crossref_primary_10_1007_s10620_018_5063_y crossref_primary_10_1002_jgh3_12350 crossref_primary_10_1016_j_path_2013_06_003 crossref_primary_10_1093_dote_doz017 crossref_primary_10_1007_s10654_021_00833_6 crossref_primary_10_1177_26345161241263836 crossref_primary_10_1136_gutjnl_2018_317800 crossref_primary_10_1111_apt_15235 crossref_primary_10_4251_wjgo_v13_i4_279 crossref_primary_10_1038_ajg_2012_455 crossref_primary_10_5582_bst_2023_01164 crossref_primary_10_24075_brsmu_2019_086 crossref_primary_10_1038_s41416_022_01974_5 crossref_primary_10_1053_j_gastro_2021_05_059 crossref_primary_10_1136_bmjgast_2021_000829 crossref_primary_10_12968_hmed_2015_76_12_703 crossref_primary_10_1016_j_medcli_2022_02_012 crossref_primary_10_1136_gutjnl_2016_311715 crossref_primary_10_1007_s11605_019_04456_x crossref_primary_10_52927_jdcr_2023_11_1_9 crossref_primary_10_1111_den_13910 crossref_primary_10_1053_j_gastro_2012_09_060 crossref_primary_10_3892_mco_2019_1842 crossref_primary_10_1038_ajg_2013_187 crossref_primary_10_22516_25007440_488 crossref_primary_10_1038_nrgastro_2014_69 crossref_primary_10_1007_s10620_012_2068_9 crossref_primary_10_1158_1940_6207_CAPR_12_0276 crossref_primary_10_1097_MOG_0000000000000090 crossref_primary_10_1039_C9AN01749F crossref_primary_10_1016_j_tgie_2018_03_002 crossref_primary_10_1038_ajg_2012_387 crossref_primary_10_1002_ueg2_12114 crossref_primary_10_1016_j_cgh_2017_02_019 crossref_primary_10_4292_wjgpt_v7_i2_190 crossref_primary_10_1111_jgh_12913 crossref_primary_10_1007_s00259_021_05582_y crossref_primary_10_1053_j_gastro_2017_05_050 crossref_primary_10_1007_s11377_019_0320_y crossref_primary_10_1111_hel_12504 crossref_primary_10_1136_flgastro_2016_100763 crossref_primary_10_1136_gutjnl_2014_307197 crossref_primary_10_1007_s12328_020_01135_2 crossref_primary_10_1007_s10620_020_06483_0 crossref_primary_10_1136_gutjnl_2012_303594 crossref_primary_10_1016_j_cgh_2021_04_032 crossref_primary_10_1186_s12876_024_03371_z crossref_primary_10_1117_1_JBO_22_12_121716 crossref_primary_10_1007_s12328_013_0412_z crossref_primary_10_1016_j_gie_2014_07_057 crossref_primary_10_1016_j_rgmxen_2016_03_002 crossref_primary_10_1038_ctg_2013_5 crossref_primary_10_1097_XCS_0000000000000923 crossref_primary_10_1053_j_gastro_2021_12_271 crossref_primary_10_1111_apt_16531 crossref_primary_10_3748_wjg_v20_i28_9611 crossref_primary_10_1007_s10620_023_08107_9 crossref_primary_10_1136_gutjnl_2015_309220 crossref_primary_10_1007_s10620_018_5148_7 crossref_primary_10_1007_s00508_013_0418_z crossref_primary_10_1007_s11938_014_0012_0 crossref_primary_10_3390_microorganisms9102003 crossref_primary_10_1117_1_JMI_4_2_024502 crossref_primary_10_1136_bmjopen_2022_064117 crossref_primary_10_1007_s10620_016_4138_x crossref_primary_10_1016_j_path_2013_05_002 crossref_primary_10_1053_j_gastro_2020_04_033 crossref_primary_10_17116_dokgastro2020904133 crossref_primary_10_1016_j_cgh_2021_02_005 crossref_primary_10_1177_26345161221116367 crossref_primary_10_1097_MOG_0b013e328353d58e crossref_primary_10_1586_17434440_2013_811863 crossref_primary_10_1016_j_clnesp_2024_11_028 crossref_primary_10_5056_jnm_2012_18_4_455 crossref_primary_10_1002_cam4_4447 crossref_primary_10_1007_s10388_020_00762_5 crossref_primary_10_1007_s00428_015_1878_5 crossref_primary_10_1016_j_gie_2012_05_024 crossref_primary_10_1038_s41568_021_00400_x crossref_primary_10_1007_s10620_016_4155_9 crossref_primary_10_1097_MD_0000000000037433 crossref_primary_10_1136_flgastro_2014_100552 crossref_primary_10_1158_1940_6207_CAPR_15_0130 crossref_primary_10_1053_j_semdp_2014_02_005 crossref_primary_10_1016_j_gie_2014_01_009 crossref_primary_10_1016_j_mpdhp_2012_08_010 crossref_primary_10_1177_2050640617752183 crossref_primary_10_1136_bmjgast_2023_001307 crossref_primary_10_1186_s12885_019_5996_3 crossref_primary_10_1007_s11938_021_00342_1 crossref_primary_10_3390_life10100244 crossref_primary_10_1016_j_soard_2021_01_028 crossref_primary_10_1007_s10620_018_5065_9 crossref_primary_10_1016_j_gie_2013_07_046 crossref_primary_10_1007_s11377_014_0936_x crossref_primary_10_1007_s11894_023_00869_6 crossref_primary_10_1016_j_gtc_2012_11_006 crossref_primary_10_1177_26345161231160114 crossref_primary_10_1136_gutjnl_2014_307278 crossref_primary_10_1007_s11596_022_2587_3 crossref_primary_10_1038_ajg_2014_10 crossref_primary_10_4253_wjge_v4_i9_379 crossref_primary_10_1038_s41746_024_01302_6 crossref_primary_10_1097_MD_0000000000003313 crossref_primary_10_1097_MOG_0000000000000743 crossref_primary_10_1111_den_13812 crossref_primary_10_1097_SLA_0000000000002179 crossref_primary_10_1016_j_hoc_2017_01_003 crossref_primary_10_1586_egh_12_39 crossref_primary_10_1097_MPG_0000000000000972 crossref_primary_10_1007_s11894_017_0589_2 crossref_primary_10_3758_s13428_017_0912_8 crossref_primary_10_1093_carcin_bgt286 crossref_primary_10_1016_j_gie_2014_01_041 crossref_primary_10_1016_j_gie_2017_03_010 crossref_primary_10_1007_s10620_013_3024_z crossref_primary_10_3390_diagnostics14030301 crossref_primary_10_1016_j_gie_2012_10_021 crossref_primary_10_1053_j_semtcvs_2011_08_008 crossref_primary_10_1016_j_thorsurg_2018_07_011 crossref_primary_10_1007_s00535_013_0816_z crossref_primary_10_1016_j_cgh_2016_03_020 crossref_primary_10_3748_wjg_v23_i28_5051 crossref_primary_10_1053_j_gastro_2011_10_034 crossref_primary_10_1016_j_bpg_2015_06_004 crossref_primary_10_5009_gnl_2014_8_4_356 crossref_primary_10_1080_00365521_2018_1430251 crossref_primary_10_1111_apt_12002 crossref_primary_10_1038_ajg_2012_299 crossref_primary_10_1016_j_rgmxen_2017_08_008 crossref_primary_10_1177_2050640616632419 crossref_primary_10_3390_ijms23073942 crossref_primary_10_1053_j_gastro_2021_01_208 crossref_primary_10_5056_jnm18156 crossref_primary_10_1016_j_eclinm_2024_102606 crossref_primary_10_14309_ajg_0000000000000514 crossref_primary_10_1007_s00761_014_2757_4 crossref_primary_10_1186_s12876_017_0708_4 crossref_primary_10_3748_wjg_v27_i18_2054 crossref_primary_10_1007_s00464_015_4103_3 crossref_primary_10_1007_s10620_013_2892_6 crossref_primary_10_1016_j_amjsurg_2015_12_008 crossref_primary_10_1038_nrm_2016_24 crossref_primary_10_1016_j_suc_2012_07_009 crossref_primary_10_1016_j_thorsurg_2022_06_002 crossref_primary_10_1016_j_suc_2021_03_002 crossref_primary_10_1016_j_mayocp_2018_04_022 crossref_primary_10_1016_j_gtc_2015_02_001 crossref_primary_10_3390_cancers13235971 crossref_primary_10_1177_0969141315575052 crossref_primary_10_1007_s10190_011_0223_3 crossref_primary_10_1016_j_tgie_2018_05_001 crossref_primary_10_1007_s00428_018_2317_1 crossref_primary_10_1111_jgh_15902 crossref_primary_10_1016_j_gtc_2015_02_003 crossref_primary_10_1007_s00428_022_03340_5 crossref_primary_10_1016_j_gie_2014_08_022 crossref_primary_10_1016_j_gtc_2015_02_005 crossref_primary_10_1016_j_gtc_2015_02_004 crossref_primary_10_3322_caac_21766 crossref_primary_10_1053_j_semtcvs_2012_01_003 crossref_primary_10_1097_MOG_0000000000000938 crossref_primary_10_1016_j_gtc_2015_02_009 crossref_primary_10_1016_j_cgh_2012_10_002 crossref_primary_10_3748_wjg_v26_i39_5959 crossref_primary_10_1371_journal_pcbi_1004919 crossref_primary_10_1016_j_disamonth_2018_04_001 crossref_primary_10_1053_j_gastro_2012_06_023 crossref_primary_10_1053_j_gastro_2015_02_012 crossref_primary_10_1158_1055_9965_EPI_15_0832 crossref_primary_10_1016_j_cgh_2024_07_041 crossref_primary_10_26724_2079_8334_2020_1_71_120_124 crossref_primary_10_1016_j_asjsur_2016_10_005 crossref_primary_10_1111_apt_12693 crossref_primary_10_1007_s00268_014_2640_x crossref_primary_10_1016_j_gtc_2015_02_014 crossref_primary_10_1080_00365521_2022_2042594 crossref_primary_10_3748_wjg_v21_i21_6479 crossref_primary_10_1136_bmj_2023_074962 crossref_primary_10_1093_carcin_bgv023 crossref_primary_10_1097_MEG_0000000000002121 crossref_primary_10_1007_s10620_015_3697_6 crossref_primary_10_1177_17562848211033730 crossref_primary_10_1016_j_igie_2024_01_001 crossref_primary_10_1177_26345161221138045 crossref_primary_10_7759_cureus_26218 crossref_primary_10_1007_s10689_017_0054_2 crossref_primary_10_1016_j_pathol_2021_08_006 crossref_primary_10_3389_fgstr_2023_1007456 crossref_primary_10_1002_cncr_29814 crossref_primary_10_1007_s10620_021_06863_0 crossref_primary_10_1177_2634516121993258 crossref_primary_10_1111_1751_2980_12264 crossref_primary_10_1016_j_giec_2017_02_006 crossref_primary_10_1111_apt_12759 crossref_primary_10_1136_gutjnl_2014_308501 crossref_primary_10_32074_1591_951X_162 crossref_primary_10_1177_2050640620927344 crossref_primary_10_1016_j_giec_2017_02_005 crossref_primary_10_1111_j_1445_2197_2012_06144_x crossref_primary_10_3748_wjg_v22_i39_8831 crossref_primary_10_1177_2050640615612409 crossref_primary_10_1038_ajg_2017_166 crossref_primary_10_1111_apt_13962 crossref_primary_10_4161_cbt_20088 crossref_primary_10_1056_NEJMoa1103042 crossref_primary_10_1158_2159_8290_CD_19_0015 crossref_primary_10_1097_MCG_0000000000001027 crossref_primary_10_1097_SLA_0000000000001387 crossref_primary_10_1053_j_gastro_2015_04_045 crossref_primary_10_1186_s12920_019_0476_9 crossref_primary_10_1039_C6AN01871H crossref_primary_10_1155_2012_814146 crossref_primary_10_1186_s13550_021_00875_7 crossref_primary_10_1053_j_gastro_2012_06_041 crossref_primary_10_29328_journal_acgh_1001018 crossref_primary_10_1016_j_jtcvs_2011_12_055 crossref_primary_10_1038_ajg_2015_55 crossref_primary_10_3390_ijms24076018 crossref_primary_10_1016_j_bpg_2014_11_008 crossref_primary_10_1158_0008_5472_CAN_12_1962 crossref_primary_10_1016_j_canlet_2021_09_005 crossref_primary_10_1111_nyas_12531 crossref_primary_10_1007_s00268_014_2661_5 crossref_primary_10_1016_j_rgmx_2017_03_007 crossref_primary_10_1111_nyas_12534 crossref_primary_10_3390_ijms17081266 crossref_primary_10_1016_j_bpg_2014_11_003 crossref_primary_10_1136_gutjnl_2018_317111 crossref_primary_10_1016_j_mpmed_2015_01_005 crossref_primary_10_1016_j_bpg_2014_11_004 crossref_primary_10_1016_j_bpg_2014_11_005 crossref_primary_10_1016_j_bpg_2018_11_003 crossref_primary_10_1002_14651858_CD007334_pub5 crossref_primary_10_1016_j_giec_2020_09_004 crossref_primary_10_1002_14651858_CD007334_pub4 crossref_primary_10_1053_j_gastro_2022_03_022 crossref_primary_10_35712_aig_v4_i2_28 crossref_primary_10_1038_ng_3013 crossref_primary_10_1111_his_14285 crossref_primary_10_1111_nyas_12529 crossref_primary_10_1016_j_cgh_2019_11_058 crossref_primary_10_1136_gutjnl_2012_302412 crossref_primary_10_1016_j_bpg_2014_11_010 crossref_primary_10_3390_gidisord1010011 crossref_primary_10_1038_ajg_2017_18 crossref_primary_10_1038_s41467_022_28237_4 crossref_primary_10_1371_journal_pone_0186305 crossref_primary_10_1177_26317745211051834 crossref_primary_10_1007_s10620_014_3347_4 crossref_primary_10_1097_MD_0000000000030503 crossref_primary_10_1111_den_13402 crossref_primary_10_1053_j_gastro_2018_02_022 crossref_primary_10_1158_2159_8290_CD_22_0824 crossref_primary_10_1016_j_disamonth_2019_02_003 crossref_primary_10_5056_jnm_2013_19_4_542 crossref_primary_10_1186_s13104_017_2456_5 crossref_primary_10_1093_carcin_bgs241 crossref_primary_10_1016_j_humpath_2018_09_016 crossref_primary_10_1038_ajg_2016_156 crossref_primary_10_1016_j_giec_2020_08_004 crossref_primary_10_1016_j_bpg_2013_08_019 crossref_primary_10_1136_bcr_2016_218016 crossref_primary_10_1016_j_giec_2020_08_001 crossref_primary_10_3748_wjg_v22_i48_10592 crossref_primary_10_1152_ajpcell_00080_2013 crossref_primary_10_1111_j_1365_2036_2012_05207_x crossref_primary_10_1007_s00464_018_06655_0 crossref_primary_10_1038_ajg_2017_117 crossref_primary_10_1136_flgastro_2012_100113 crossref_primary_10_1007_s10190_012_0234_8 crossref_primary_10_1056_NEJMe1108435 crossref_primary_10_1016_j_cgh_2018_07_008 crossref_primary_10_1016_j_giec_2017_03_002 crossref_primary_10_1177_26345161221143140 crossref_primary_10_1177_26317745211049964 crossref_primary_10_1016_j_gie_2014_02_020 crossref_primary_10_1016_j_bpg_2014_12_004 crossref_primary_10_1007_s10388_019_00707_7 crossref_primary_10_1097_MD_0000000000005402 crossref_primary_10_1111_dote_12185 crossref_primary_10_1016_j_dld_2012_12_020 crossref_primary_10_1038_nrclinonc_2012_35 crossref_primary_10_1053_j_gastro_2015_04_013 crossref_primary_10_1016_j_ijsu_2012_04_003 crossref_primary_10_1053_j_gastro_2015_11_040 crossref_primary_10_1093_dote_doab072 crossref_primary_10_1007_s11938_017_0136_0 crossref_primary_10_1186_s40001_021_00561_3 crossref_primary_10_1136_flgastro_2023_102425 crossref_primary_10_1371_journal_pone_0169250 crossref_primary_10_1007_s10620_020_06595_7 crossref_primary_10_14309_ajg_0000000000001680 crossref_primary_10_1177_2634516121993676 crossref_primary_10_1093_bjsopen_zrab069 crossref_primary_10_1111_dote_12151 crossref_primary_10_1038_srep32638 crossref_primary_10_1016_j_isci_2023_106574 crossref_primary_10_1053_j_gastro_2013_02_050 crossref_primary_10_1097_MCG_0000000000001362 crossref_primary_10_1097_SLA_0000000000002658 crossref_primary_10_1186_s13046_024_02963_7 crossref_primary_10_5230_jgc_2021_21_e39 crossref_primary_10_3390_bioengineering10111239 crossref_primary_10_1136_gutjnl_2016_312223 crossref_primary_10_1002_jso_25656 crossref_primary_10_1093_gastro_got009 crossref_primary_10_1093_dote_doad044 crossref_primary_10_1053_j_gastro_2017_09_046 crossref_primary_10_1136_flgastro_2013_100414 crossref_primary_10_1038_bjc_2013_783 crossref_primary_10_4161_cbt_25362 crossref_primary_10_1038_ajg_2013_94 crossref_primary_10_1111_j_1751_2980_2011_00541_x crossref_primary_10_36401_IDDB_23_15 crossref_primary_10_1111_dote_12166 crossref_primary_10_1136_gutjnl_2023_330721 crossref_primary_10_1016_j_tgie_2018_02_002 crossref_primary_10_1056_NEJMra1314704 crossref_primary_10_1038_s41575_021_00531_4 crossref_primary_10_1038_ajg_2015_322 crossref_primary_10_1111_nyas_13680 crossref_primary_10_1002_deo2_73 crossref_primary_10_1007_s10353_012_0101_z crossref_primary_10_1007_s10620_018_5152_y crossref_primary_10_1016_j_gie_2018_09_041 crossref_primary_10_1093_dote_doae002 crossref_primary_10_1007_s11894_015_0433_5 crossref_primary_10_1093_dote_doac065 crossref_primary_10_1371_journal_pone_0212916 crossref_primary_10_1053_j_gastro_2014_03_021 crossref_primary_10_1016_j_rgmx_2015_07_007 crossref_primary_10_1080_01459740_2024_2376004 crossref_primary_10_1016_j_thorsurg_2011_09_003 crossref_primary_10_1038_ajg_2013_420 crossref_primary_10_1111_dote_12372 crossref_primary_10_1136_gutjnl_2022_327281 crossref_primary_10_1007_s00268_014_2692_y crossref_primary_10_17116_dokgastro2017644_19 crossref_primary_10_1111_jgh_13491 crossref_primary_10_1111_nyas_14447 crossref_primary_10_1093_jnci_djs426 crossref_primary_10_7861_clinmedicine_14_6_s78 crossref_primary_10_1093_dote_dox007 crossref_primary_10_1007_s10620_014_3186_3 crossref_primary_10_1053_j_gastro_2012_04_032 crossref_primary_10_1080_15384101_2016_1175252 crossref_primary_10_14309_ajg_0000000000003030 crossref_primary_10_1016_j_jtcvs_2012_12_058 crossref_primary_10_3390_cancers15051408 crossref_primary_10_1038_ajg_2015_263 crossref_primary_10_1111_nyas_14439 crossref_primary_10_18786_2072_0505_2020_48_011 crossref_primary_10_4251_wjgo_v14_i3_568 crossref_primary_10_1007_s10620_020_06462_5 crossref_primary_10_1016_j_gie_2012_01_021 crossref_primary_10_2217_cer_2016_0089 crossref_primary_10_1186_s40792_018_0454_z crossref_primary_10_4161_cc_22485 crossref_primary_10_1093_dote_doy102 crossref_primary_10_1007_s10620_018_5151_z crossref_primary_10_1038_modpathol_2017_36 crossref_primary_10_1038_s41572_019_0086_z crossref_primary_10_1016_j_cgh_2014_03_036 crossref_primary_10_1093_jnci_djr223 crossref_primary_10_1038_ajg_2017_70 crossref_primary_10_1097_PAS_0000000000000623 crossref_primary_10_1016_j_dld_2015_06_007 crossref_primary_10_1007_s10353_012_0183_7 crossref_primary_10_1038_s41416_019_0685_1 crossref_primary_10_1053_j_gastro_2018_03_001 crossref_primary_10_1136_gutjnl_2013_305372 crossref_primary_10_1136_gutjnl_2013_305490 crossref_primary_10_1136_gutjnl_2014_308802 crossref_primary_10_1016_j_gie_2016_12_001 crossref_primary_10_1016_j_tige_2023_01_004 crossref_primary_10_1111_nyas_13134 crossref_primary_10_1038_ajg_2015_376 crossref_primary_10_1159_000357184 crossref_primary_10_1016_j_medcle_2022_07_003 crossref_primary_10_1016_j_gastre_2022_09_007 crossref_primary_10_1111_dote_12483 crossref_primary_10_1097_SLA_0000000000000424 crossref_primary_10_1177_000313481207800717 crossref_primary_10_1097_MEG_0000000000002700 crossref_primary_10_1080_00325481_2021_1934495 crossref_primary_10_1136_gutjnl_2014_307969 crossref_primary_10_3748_wjg_v22_i25_5753 crossref_primary_10_1177_2050640617737466 crossref_primary_10_1053_j_gastro_2014_04_014 crossref_primary_10_1007_s12664_019_00979_y crossref_primary_10_1016_j_gie_2012_08_004 crossref_primary_10_1016_j_trsl_2015_01_009 crossref_primary_10_1016_j_mayocp_2014_01_022 crossref_primary_10_1038_ajg_2014_324 crossref_primary_10_1093_dote_dox109 crossref_primary_10_1016_j_cgh_2020_05_023 crossref_primary_10_1016_j_igie_2023_11_003 crossref_primary_10_1016_j_ebiom_2022_104160 crossref_primary_10_1053_j_gastro_2013_03_045 crossref_primary_10_1158_1055_9965_EPI_15_0370 crossref_primary_10_1111_dote_12210 crossref_primary_10_1053_j_gastro_2013_05_040 crossref_primary_10_1053_j_gastro_2015_07_053 crossref_primary_10_3390_diagnostics12092031 crossref_primary_10_1159_000441075 crossref_primary_10_1136_bmjopen_2014_006640 crossref_primary_10_1097_MOG_0b013e328362282f crossref_primary_10_5946_ce_2014_47_1_40 crossref_primary_10_1016_S1134_2072_14_70761_3 crossref_primary_10_1007_s10620_018_5161_x crossref_primary_10_1055_a_1466_9727 crossref_primary_10_3390_cancers14133240 crossref_primary_10_1016_j_cgh_2013_02_017 crossref_primary_10_3390_cancers15030873 crossref_primary_10_1016_j_mayocp_2019_01_032 crossref_primary_10_1097_MEG_0000000000000868 crossref_primary_10_1136_gutjnl_2019_318985 crossref_primary_10_3390_medicines4030067 crossref_primary_10_1136_bmjebm_2024_113260 crossref_primary_10_1177_26345161231160718 crossref_primary_10_26104_NNTIK_2023_48_21_024 crossref_primary_10_1016_j_ebiom_2020_102765 crossref_primary_10_5946_ce_2014_47_1_55 crossref_primary_10_4292_wjgpt_v7_i2_227 crossref_primary_10_1159_000362575 crossref_primary_10_1007_s11695_019_04225_4 crossref_primary_10_1038_ajg_2014_384 crossref_primary_10_1097_MOG_0b013e3283622848 crossref_primary_10_1016_j_ejso_2017_02_004 crossref_primary_10_1007_s10620_016_4315_y crossref_primary_10_3389_fonc_2021_630837 crossref_primary_10_1093_dote_doae095 crossref_primary_10_1111_jgh_15577 crossref_primary_10_1007_s12664_015_0597_9 crossref_primary_10_1186_1471_230X_12_181 crossref_primary_10_1093_bmb_ldt025 crossref_primary_10_1016_j_gie_2015_12_036 crossref_primary_10_3748_wjg_v22_i33_7415 crossref_primary_10_1007_s12312_020_00825_9 crossref_primary_10_3892_ijo_2012_1481 crossref_primary_10_1371_journal_pone_0094163 crossref_primary_10_3748_wjg_v25_i25_3231 crossref_primary_10_1007_s00464_014_3629_0 crossref_primary_10_1007_s10620_020_06563_1 crossref_primary_10_1016_j_gie_2017_09_012 crossref_primary_10_1038_labinvest_2015_98 crossref_primary_10_1007_s00268_017_3957_z crossref_primary_10_1016_j_ejca_2016_12_037 crossref_primary_10_1080_03007995_2018_1552407 crossref_primary_10_1016_j_dld_2018_04_012 |
| Cites_doi | 10.1007/s10620-007-0023-y 10.1111/j.1572-0241.2000.03348.x 10.1136/bmj.321.7271.1238 10.1136/gut.39.4.574 10.1136/bmj.327.7414.534 10.1111/j.1572-0241.1999.01276.x 10.1111/j.1572-0241.2003.07454.x 10.1002/jso.20358 10.1080/00365520410003524 10.1111/j.1572-0241.2002.05902.x 10.1093/aje/kwn121 10.1038/ajg.2009.390 10.1038/sj.bjc.6605246 10.1111/j.1572-0241.2006.00626.x 10.1111/j.1442-2050.2007.00638.x 10.1111/j.1572-0241.1998.00275.x 10.1136/gut.46.1.9 10.1136/gut.2004.041517 10.1136/gut.2004.063685 10.1111/j.1572-0241.2005.41300.x 10.1136/fg.2009.000307 10.1097/MEG.0b013e3282c3aa14 10.1080/003655200750024461 10.1136/bmj.321.7271.1252 10.1097/01.pas.0000213394.34451.d2 10.1136/gut.2009.176701 10.1111/j.1572-0241.2004.30426.x 10.1097/00042737-200012060-00013 10.1111/j.1572-0241.2005.40187.x 10.1097/01.sla.0000167864.46462.9f 10.1136/gut.48.3.304 10.1055/s-2007-966592 10.1111/j.1572-0241.2008.01835.x 10.1023/A:1024715824149 |
| ContentType | Journal Article |
| Copyright | The Author 2011. Published by Oxford University Press. 2011 2015 INIST-CNRS Copyright Oxford Publishing Limited(England) Jul 6, 2011 |
| Copyright_xml | – notice: The Author 2011. Published by Oxford University Press. 2011 – notice: 2015 INIST-CNRS – notice: Copyright Oxford Publishing Limited(England) Jul 6, 2011 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TO 7U7 7U9 C1K H94 K9. NAPCQ 7X8 7U1 5PM |
| DOI | 10.1093/jnci/djr203 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic Risk Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Environmental Sciences and Pollution Management MEDLINE - Academic Risk Abstracts |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Risk Abstracts Nursing & Allied Health Premium |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2105 |
| EndPage | 1057 |
| ExternalDocumentID | PMC3632011 2410524501 21680910 24343137 10_1093_jnci_djr203 10.1093/jnci/djr203 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Feature |
| GeographicLocations | Northern Ireland British Isles, Northern Ireland |
| GeographicLocations_xml | – name: Northern Ireland – name: British Isles, Northern Ireland |
| GroupedDBID | --- -DD -E4 -~X .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 186 1TH 29L 2QL 2WC 354 3O- 4.4 482 48X 53G 5GY 5RE 5VS 5WD 6.Y 70D 8WZ 96U A6W AABZA AACZT AAGKA AAHTB AAJKP AAJQQ AAKAS AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AASNB AAUAY AAUQX AAVAP AAWDT AAWTL ABCQX ABEFU ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPEJ ABPMR ABPPZ ABPTD ABQLI ABQNK ABQTQ ABSAR ABSMQ ABXVV ABZBJ ACBMB ACFRR ACGFO ACGFS ACGOD ACKOT ACMRT ACNCT ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ACZBC ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZCM ADZXQ AEGPL AEJOX AEKPW AEKSI AEMDU AENZO AEPUE AETBJ AETEA AEWNT AFAZI AFCHL AFFNX AFFZL AFIYH AFOFC AFRAH AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGNAY AGSYK AGUTN AHMBA AHXPO AI. AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS ASPBG ATGXG ATTQO AVNTJ AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BKOMP BTRTY BVRKM BZKNY C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EIHJH EJD EMOBN ENERS F3I F5P F8P F9B FA8 FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GOZPB GRPMH GX1 H13 H5~ HAR HVGLF HW0 HZ~ IH2 IOX J21 J5H JXSIZ KAQDR KBUDW KC5 KOP KQ8 KSI KSN L7B LXL LXN LXY M-Z M49 MBLQV MHKGH ML0 MVM N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ OAUYM OAWHX OBH OCB OCZFY ODMLO ODZKP OGEVE OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q.- Q1. Q5Y QBD R44 RD5 RHF RNI RNS ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCURE TEORI TJX TMA TR2 TWZ UDS UPT VH1 VVN W8F WH7 WOQ X7H X7M XJT Y6R YAYTL YHZ YKOAZ YQT YXANX ZKX ZRR ZY1 ~91 ~H1 ~X8 AAYXX ABDFA ABEJV ABGNP ABVGC ADNBA AEMQT AGORE AHMMS AJBYB AJNCP ALXQX CITATION ABNGD ACUKT ACVCV ADMTO ADXHL AEHUL AFFQV AGQPQ AHGBF AJDVS IQODW OBFPC YR5 CGR CUY CVF ECM EIF NPM 7TO 7U7 7U9 C1K H94 K9. NAPCQ 7X8 7U1 5PM |
| ID | FETCH-LOGICAL-c566t-effbbdb1ac0cb414a80cd2fc0c4d22176c0a4c8ce6e3016826ebd20ad9ecf3dc3 |
| ISSN | 0027-8874 1460-2105 |
| IngestDate | Thu Aug 21 13:17:14 EDT 2025 Fri Jul 11 09:04:39 EDT 2025 Fri Jul 11 02:27:37 EDT 2025 Mon Jun 30 10:50:31 EDT 2025 Mon Jul 21 05:53:55 EDT 2025 Mon Jul 21 09:16:20 EDT 2025 Tue Jul 01 01:42:12 EDT 2025 Thu Apr 24 23:04:09 EDT 2025 Wed Aug 28 03:24:22 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Keywords | Human Premalignant lesion Cancerology Esophageal disease Evolutivity Barrett's esophagus Digestive diseases Malignant tumor Cancer |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c566t-effbbdb1ac0cb414a80cd2fc0c4d22176c0a4c8ce6e3016826ebd20ad9ecf3dc3 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 |
| OpenAccessLink | https://academic.oup.com/jnci/article-pdf/103/13/1049/7673493/djr203.pdf |
| PMID | 21680910 |
| PQID | 879703776 |
| PQPubID | 41605 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3632011 proquest_miscellaneous_899149425 proquest_miscellaneous_875723788 proquest_journals_879703776 pubmed_primary_21680910 pascalfrancis_primary_24343137 crossref_citationtrail_10_1093_jnci_djr203 crossref_primary_10_1093_jnci_djr203 oup_primary_10_1093_jnci_djr203 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-07-06 |
| PublicationDateYYYYMMDD | 2011-07-06 |
| PublicationDate_xml | – month: 07 year: 2011 text: 2011-07-06 day: 06 |
| PublicationDecade | 2010 |
| PublicationPlace | Cary, NC |
| PublicationPlace_xml | – name: Cary, NC – name: United States – name: Oxford |
| PublicationTitle | JNCI : Journal of the National Cancer Institute |
| PublicationTitleAlternate | J Natl Cancer Inst |
| PublicationYear | 2011 |
| Publisher | Oxford University Press Oxford Publishing Limited (England) |
| Publisher_xml | – name: Oxford University Press – name: Oxford Publishing Limited (England) |
| References | Steevens (2_34956604) 2010; 22 Oberg (23_18973020) 2005; 242 (9_40142819) 2006; 10 (27_34961501) 1996; 110 Marsman (15_19681717) 2005; 92 Sharma (30_6405101) 2000; 46 Nilsson (40_6467149) 2000; 35 Gopal (19_17771355) 2003; 48 Gatenby (33_29955778) 2007; 19 Streitz (39_6058641) 1998; 93 Conio (32_11038051) 2001; 48 de Jonge (21_22422425) 2006; 101 Dulai (34_18751761) 2005; 100 (12_31282323) 2008; 168 Chandrasoma (29_23538390) 2007; 20 Avidan (22_17203819) 2002; 97 (25_19255854) 2005; 54 van Blankenstein (26_18713101) 2005; 100 Skacel (35_10609872) 2000; 95 Murray (14_17798860) 2003; 327 Provenzale (10_10923119) 1999; 94 Cook (1_35449947) 2009; 101 Weston (31_18302055) 2004; 99 (37_40138289) 2007; 39 (11_33228346) 2000; 119 Chandrasoma (16_28308761) 2007; 31 Gatenby (20_31095930) 2008; 53 Hage (36_18712867) 2004; 39 Eloubeidi (3_17730296) 2003; 98 Wang (7_30655679) 2008; 103 Bani-Hani (24_10403889) 2000; 12 Wright (38_16537375) 1996; 39 Riddell (13_35323491) 2009; 104 Macdonald (41_10553677) 2000; 321 Somerville (8_37424529) 2010; 1 de Jonge (17_37636834) 2010; 59 Lagergren (5_18681061) 2005; 54 McGarrity (28_10553665) 2000; 321 J Natl Cancer Inst. 2013 Apr 17;105(8):581 21680911 - J Natl Cancer Inst. 2011 Jul 6;103(13):994-5 23042934 - J Natl Cancer Inst. 2012 Nov 21;104(22):1771-2 |
| References_xml | – volume: 53 start-page: 1175 issn: 0163-2116 issue: 5 year: 2008 ident: 20_31095930 publication-title: Digestive diseases and sciences doi: 10.1007/s10620-007-0023-y – volume: 95 start-page: 3383 issn: 0002-9270 issue: 12 year: 2000 ident: 35_10609872 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.2000.03348.x – volume: 321 start-page: 1238 issn: 0959-8138 issue: 7271 year: 2000 ident: 28_10553665 publication-title: BMJ doi: 10.1136/bmj.321.7271.1238 – volume: 39 start-page: 574 issn: 0017-5749 issue: 4 year: 1996 ident: 38_16537375 publication-title: Gut doi: 10.1136/gut.39.4.574 – volume: 327 start-page: 534 issn: 0959-8138 issue: 7414 year: 2003 ident: 14_17798860 publication-title: BMJ doi: 10.1136/bmj.327.7414.534 – volume: 94 start-page: 2043 issn: 0002-9270 issue: 8 year: 1999 ident: 10_10923119 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.1999.01276.x – volume: 98 start-page: 1627 issn: 0002-9270 issue: 7 year: 2003 ident: 3_17730296 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.2003.07454.x – volume: 92 start-page: 160 issn: 0022-4790 issue: 3 year: 2005 ident: 15_19681717 publication-title: Journal of surgical oncology doi: 10.1002/jso.20358 – volume: 39 start-page: 1175 issn: 0036-5521 issue: 12 year: 2004 ident: 36_18712867 publication-title: Scandinavian journal of gastroenterology doi: 10.1080/00365520410003524 – volume: 97 start-page: 1930 issn: 0002-9270 issue: 8 year: 2002 ident: 22_17203819 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.2002.05902.x – volume: 168 start-page: 237 issn: 0002-9262 issue: 3 year: 2008 ident: 12_31282323 publication-title: American Journal of Epidemiology doi: 10.1093/aje/kwn121 – volume: 104 start-page: 2588 issn: 0002-9270 issue: 10 year: 2009 ident: 13_35323491 publication-title: The American journal of gastroenterology doi: 10.1038/ajg.2009.390 – volume: 101 start-page: 855 issn: 1532-1827 issue: 5 year: 2009 ident: 1_35449947 publication-title: British Journal of Cancer doi: 10.1038/sj.bjc.6605246 – volume: 101 start-page: 1421 issn: 0002-9270 issue: 7 year: 2006 ident: 21_22422425 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.2006.00626.x – volume: 110 start-page: 614 issn: 1528-0012 year: 1996 ident: 27_34961501 – volume: 20 start-page: 36 issn: 1120-8694 issue: 1 year: 2007 ident: 29_23538390 publication-title: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E doi: 10.1111/j.1442-2050.2007.00638.x – volume: 93 start-page: 911 issn: 0002-9270 issue: 6 year: 1998 ident: 39_6058641 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.1998.00275.x – volume: 46 start-page: 9 issn: 0017-5749 issue: 1 year: 2000 ident: 30_6405101 publication-title: Gut doi: 10.1136/gut.46.1.9 – volume: 54 start-page: i1 issn: 0017-5749 issue: suppl_1 year: 2005 ident: 5_18681061 publication-title: Gut doi: 10.1136/gut.2004.041517 – volume: 54 start-page: 1062 issn: 0017-5749 issue: 8 year: 2005 ident: 25_19255854 publication-title: Gut doi: 10.1136/gut.2004.063685 – volume: 100 start-page: 775 issn: 0002-9270 issue: 4 year: 2005 ident: 34_18751761 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.2005.41300.x – volume: 1 start-page: 88 issn: 2041-4145 issue: 2 year: 2010 ident: 8_37424529 publication-title: Frontline Gastroenterology doi: 10.1136/fg.2009.000307 – volume: 19 start-page: 969 issn: 0954-691X issue: 11 year: 2007 ident: 33_29955778 publication-title: European journal of gastroenterology & hepatology doi: 10.1097/MEG.0b013e3282c3aa14 – volume: 35 start-page: 10 issn: 0036-5521 issue: 1 year: 2000 ident: 40_6467149 publication-title: Scandinavian journal of gastroenterology doi: 10.1080/003655200750024461 – volume: 321 start-page: 1252 issn: 0959-8138 issue: 7271 year: 2000 ident: 41_10553677 publication-title: BMJ doi: 10.1136/bmj.321.7271.1252 – volume: 31 start-page: 569 issn: 0147-5185 issue: 4 year: 2007 ident: 16_28308761 publication-title: The American journal of surgical pathology doi: 10.1097/01.pas.0000213394.34451.d2 – volume: 59 start-page: 1030 issn: 0017-5749 issue: 8 year: 2010 ident: 17_37636834 publication-title: Gut doi: 10.1136/gut.2009.176701 – volume: 99 start-page: 1657 issn: 0002-9270 issue: 9 year: 2004 ident: 31_18302055 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.2004.30426.x – volume: 12 start-page: 649 issn: 0954-691X issue: 6 year: 2000 ident: 24_10403889 publication-title: European journal of gastroenterology & hepatology doi: 10.1097/00042737-200012060-00013 – volume: 100 start-page: 568 issn: 0002-9270 issue: 3 year: 2005 ident: 26_18713101 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.2005.40187.x – volume: 242 start-page: 49 issn: 0003-4932 issue: 1 year: 2005 ident: 23_18973020 publication-title: Annals of surgery doi: 10.1097/01.sla.0000167864.46462.9f – volume: 48 start-page: 304 issn: 0017-5749 issue: 3 year: 2001 ident: 32_11038051 publication-title: Gut doi: 10.1136/gut.48.3.304 – volume: 39 start-page: 581 issn: 1438-8812 year: 2007 ident: 37_40138289 doi: 10.1055/s-2007-966592 – volume: 22 start-page: 669 issn: 0954-691X issue: 6 year: 2010 ident: 2_34956604 publication-title: European journal of gastroenterology & hepatology – volume: 103 start-page: 788 issn: 0002-9270 issue: 3 year: 2008 ident: 7_30655679 publication-title: The American journal of gastroenterology doi: 10.1111/j.1572-0241.2008.01835.x – volume: 10 start-page: 1 issn: 1366-5278 issue: 8 year: 2006 ident: 9_40142819 publication-title: Health technology assessment (Winchester, England) – volume: 119 start-page: 333 issn: 1528-0012 year: 2000 ident: 11_33228346 – volume: 48 start-page: 1537 issn: 0163-2116 issue: 8 year: 2003 ident: 19_17771355 publication-title: Digestive diseases and sciences doi: 10.1023/A:1024715824149 – reference: 21680911 - J Natl Cancer Inst. 2011 Jul 6;103(13):994-5 – reference: - J Natl Cancer Inst. 2013 Apr 17;105(8):581 – reference: 23042934 - J Natl Cancer Inst. 2012 Nov 21;104(22):1771-2 |
| SSID | ssj0000924 |
| Score | 2.563006 |
| Snippet | Background
Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal... Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal adenocarcinoma... Background Barrett's esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, the reported incidence of esophageal... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1049 |
| SubjectTerms | Adenocarcinoma - diagnosis Adenocarcinoma - epidemiology Adenocarcinoma - etiology Adenocarcinoma - mortality Aged Aged, 80 and over Barrett Esophagus - complications Barrett Esophagus - epidemiology Barrett Esophagus - mortality Barrett Esophagus - pathology Biological and medical sciences Cancer Cardia Cell Transformation, Neoplastic - pathology Clinical outcomes Disease Progression Esophageal Neoplasms - diagnosis Esophageal Neoplasms - epidemiology Esophageal Neoplasms - etiology Esophageal Neoplasms - mortality Esophagus Female Gastroenterology Gastroenterology. Liver. Pancreas. Abdomen Gastroesophageal reflux Humans Incidence Intestines - pathology Kaplan-Meier Estimate Male Medical sciences Metaplasia - epidemiology Middle Aged Northern Ireland - epidemiology Other diseases. Semiology Precancerous Conditions - epidemiology Precancerous Conditions - pathology Proportional Hazards Models Registries Risk Factors Stomach Neoplasms - diagnosis Stomach Neoplasms - epidemiology Stomach Neoplasms - etiology Stomach Neoplasms - mortality Tumors |
| Title | Risk of Malignant Progression in Barrett's Esophagus Patients: Results from a Large Population-Based Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21680910 https://www.proquest.com/docview/879703776 https://www.proquest.com/docview/875723788 https://www.proquest.com/docview/899149425 https://pubmed.ncbi.nlm.nih.gov/PMC3632011 |
| Volume | 103 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEkhHgWUyh7qIREZOrYGz-40aihoDZIkEq5Wftykyh1ojjhwE_gVzPjXTtOFZXHxUrs0dryfDs7s_5mhpCjSEdcB0y5nS7vukwK3024H7saq4knmimvzOK_GIRnl-zLqDtqtX41WEvrlXgvf-7MK_kfrcI50Ctmyf6DZutB4QT8Bv3CETQMx7_S8TfLC78GZ_oKGS2GbmVKbeBOxklFxI2KtsaGBfxqXVS1VEsyHAivZ6vCpJnw9gyJ4e1F3dXLxVVONYrQVn7soPe53E1oOLQlXbLaW-whmpYbLkId9o95afa_jyc_-JJf199A5jNtN2PLlXDT8wvsUaHL0pH9-ZqrJuWnsNz_kyWaqWFzBwO3ZJFx1zC6LPRcCD3N122941xlqb2gCcmgYXghqkx2rgimWtY0l6hNNV36doytytuDr2n_8vw8HZ6OhnfIXR9CDuyG8Wm0oQsBZpnJVDPPZXM9YfhjHPzYDL3l3ZiMyQcLXsB0y0yflF2BzE0-bsPBGT4iD60i6UcDs8ekpfMn5N6F5V48JVNEG51ntEYbbaCNTnJq0fa2oDXWaIW1D9QijSLSKKcl0uhNpNESac_IZf902DtzbacOV0I4sHJ1lgmhRIdLTwrWYTz2pPIz-MeUD0FvKD3OZCx1qGFBCSGk1UL5HleJllmgZPCc7OXzXL8gNMkEj7UntQg1S_w4EQHPoigWwssYC5lD3lVvOJW2jD12U5mlhk4RpKiO1KjDIUe18MJUb9kt9gZUdbvE4ZYaa1kfM7M7QeSQg0qvqbUQRRpHCSyoURQ6hNZXwXzjNzmea5g-KfaT8LGnwy0iEMKxBNZWh-wbnGzuDu8SHX6HRFsIqgWwePz2lXwyLovIB2GAc_Hln5_sgNzfzNpXZG-1XOvX4ImvxGE5RX4Dc8jozA |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+malignant+progression+in+Barrett%27s+esophagus+patients%3A+results+from+a+large+population-based+study&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Bhat%2C+Shivaram&rft.au=Coleman%2C+Helen+G&rft.au=Yousef%2C+Fouad&rft.au=Johnston%2C+Brian+T&rft.date=2011-07-06&rft.issn=1460-2105&rft.eissn=1460-2105&rft.volume=103&rft.issue=13&rft.spage=1049&rft_id=info:doi/10.1093%2Fjnci%2Fdjr203&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8874&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8874&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8874&client=summon |